PlainRecalls
FDA Drug Moderate Class II Terminated

rOPINIRole Tablets USP 0.25 mg*, 100-count bottle, Rx Only, Manufactured for: Accord Healthcare, Inc., Durham, NC 27703 Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213 INDIA. NDC 16729-232-01, UPC 3 16729 23201 2;

Reported: March 8, 2023 Initiated: February 7, 2023 #D-0425-2023

Product Description

rOPINIRole Tablets USP 0.25 mg*, 100-count bottle, Rx Only, Manufactured for: Accord Healthcare, Inc., Durham, NC 27703 Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213 INDIA. NDC 16729-232-01, UPC 3 16729 23201 2;

Reason for Recall

CGMP Deviations: recalling drug products following an FDA inspection.

Details

Recalling Firm
Accord Healthcare, Inc.
Units Affected
139,332 bottles
Distribution
United States including Puerto Rico and Canada
Location
Durham, NC

Frequently Asked Questions

What product was recalled?
rOPINIRole Tablets USP 0.25 mg*, 100-count bottle, Rx Only, Manufactured for: Accord Healthcare, Inc., Durham, NC 27703 Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213 INDIA. NDC 16729-232-01, UPC 3 16729 23201 2;. Recalled by Accord Healthcare, Inc.. Units affected: 139,332 bottles.
Why was this product recalled?
CGMP Deviations: recalling drug products following an FDA inspection.
Which agency issued this recall?
This recall was issued by the FDA Drug on March 8, 2023. Severity: Moderate. Recall number: D-0425-2023.